Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated Follicular Lymphoma
Roche Announces Direct Sales of Kapa Biosystems NGS Products in Canada
This ETF holds a swath of large- and mid-cap U.S. healthcare companies.
Maxygen MAXY announced that its partner Roche RHHBY placed a hold on development of Maxy-Alpha--the first of Maxygen's shuffled proteins to enter clinical development--and we're lowering our fair value estimate accordingly. While we had only placed a 20% probability on the eventual approval of ...
Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.
Ariel International marks the firm’s first foray into foreign-stock investing. It has been a performance success so far.
First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.
Top managers continue to focus on higher-quality dividend-paying stocks in a fully valued market.
Readers say diversification and exposure to good companies call for looking beyond the U.S.
Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.